泰林生物(300813.SZ):近期共取得4項商標註冊證書、14項專利證書及1項軟件著作權證書
格隆匯7月16日丨泰林生物(300813.SZ)公佈,公司及全資子公司浙江泰林生命科學有限公司(“泰林生命科學”)、浙江泰林醫學工程有限公司(“泰林醫學工程”)、浙江泰林分析儀器有限公司(“泰林分析儀器”)於近期共取得了4項商標註冊證書、14項專利證書以及1項軟件著作權證書。
上述軟件著作權的取得不會對公司及及全資子公司泰林醫學工程近期生產經營產生重大影響,但在一定程度上有利於發揮公司及全資子公司泰林醫學工程的自主知識產權優勢,完善知識產權保護體系,形成持續創新機制,提升核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.